Table 5. Distribution of HRC and non-HRC according to ICUs, T3SS virulotypes and antimicrobial susceptibility of P. aeruginosa isolates.
| HRC n = 22 |
non-HRC n = 32 |
P-value* | |
|---|---|---|---|
| ICU | |||
| AICU | 16a | 12b | 0.0100 |
| PICU | 5 | 9 | |
| NICU | 1b | 11a | |
| T3SS Virulotype | |||
| exoS+/exoU+ | 11 | 19 | 0.5820 |
| exoS+/exoU- | 11 | 13 | |
| Antimicrobial resistance | |||
| FEP | 18 | 9 | 0.0002 |
| IMP | 20 | 16 | 0.0027 |
| MER | 17 | 9 | 0.0007 |
| TZP | 11 | 6 | 0.0198 |
| GN | 20 | 4 | < 0.0001 |
| CIP | 21 | 6 | < 0.0001 |
| Susceptibility phenotype | |||
| MultiS | 1 | 8 | 0.0676 |
| ModR | 0 | 23 | < 0.0001 |
| MultiS+ModR | 1 | 31 | < 0.0001 |
| MDR | 5 | 1 | 0.0706 |
| XDR | 16 | 0 | < 0.0001 |
| MDR+XDR | 21 | 1 | < 0.0001 |
HRC, high-risk clones; ICU, intensive care unit; AICU, adult intensive care unit; PICU, pediatric intensive care unit; NICU, neonatal intensive care unit; T3SS, type III secretion system; FEP, cefepime; IMP, imipenem; MER, meropenem; TZP, piperacillin+tazobactam; GN, gentamicin; CIP, ciprofloxacin; POL, polymyxin B; MultiS, susceptible to all tested antibiotics; ModR, moderately resistant; MDR, multi-drug resistant; XDR, extensively drug-resistant.
* P values were calculated using the G-test of independence or Fisher’s exact test.
a Frequency higher than expected at random.
b Frequency lower than expected at random.